Structure-Based Drug Design

 

1. Inhibitors of dimerization of  ErbB tyrosine-kinase transmembrane receptors – These receptors are overexpressed in many cancers and are a useful therapeutic target in oncology. (see Yang et al. Chem Biol Drug Design, 76:1, 2010)

Collaboration with Profs. Linda J. Pike and Craig Lockhart, WUSM